Progressive MS Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.
User avatar
zen2010
Family Elder
Posts: 218
Joined: Mon Mar 15, 2010 3:00 pm
Location: Villeurbanne, France

Re: Progressive MS Pipeline

Post by zen2010 » Sun Jan 24, 2016 11:05 am

dignan wrote:Upon request, here are the drugs from the pipeline that are being tested for progressive forms of MS. If I've missed anything, please let me know.



Progressive MS Treatment Pipeline - September 2011

Phase 3 Trials
- Gilenya (aka FTY720 and fingolimod) (PPMS) (Novartis)
- Masitinib (SPMS and PPMS) (aka Kinavet or AB1010) (AB Science)
- Ocrelizumab (R1594) (trial for PPMS) (Genentech, Roche, Biogen)
- Revimmune (aka high dose cyclophosphamide or cytoxan) (Accentia Biopharmaceuticals) (refractory MS - includes SPMS I think, not sure about PPMS)

Phase 2 Trials
- Amiloride (Oxford University) (PPMS)
- Fluoxetine (aka Prozac) (SP, PP & RRMS) (University Medical Center Groningen)
- GEM-SP (SPMS) (Gemacbio)
- Hydroxyurea (PPMS) (S. Andrea Hospital)
- Idebenone (National Institute of Neurological Disorders and Stroke)
- Lithium (US Department of Veterans Affairs)
- Mesenchymal Stem Cells (4 trials listed in clinicaltrials.gov)
- MIS416 (progressive MS) (Innate Therapeutics)
- PI-2301 (Peptimmune)
- Pixantrone (aka BBR 2778) (SPMS) (Cell Therapeutics)
- RTL1000 (Artielle ImmunoTherapeutics)
- Zocor (aka simvastatin) (SPMS) (MS-STAT trial - UK)
Hi all,

Can anyone pls update this status?

I tried to find something on the net but didn't get anything...

Thks

User avatar
zen2010
Family Elder
Posts: 218
Joined: Mon Mar 15, 2010 3:00 pm
Location: Villeurbanne, France

Re: Progressive MS Pipeline

Post by zen2010 » Tue Jan 26, 2016 10:52 am

I found this interesting link below...
https://www.mssociety.org.uk/ms-researc ... peline#PMS

User avatar
UWE59
Family Member
Posts: 28
Joined: Mon May 31, 2010 2:00 pm
Location: Germany
Contact:

Re: Progressive MS Pipeline

Post by UWE59 » Tue Aug 02, 2016 8:50 am

zen2010 wrote:I found this interesting link below...
https://www.mssociety.org.uk/ms-researc ... peline#PMS
This link is not available.
Kind regards UWE

User avatar
NHE
Volunteer Moderator
Posts: 5297
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: Progressive MS Pipeline

Post by NHE » Tue Aug 02, 2016 8:54 pm

UWE59 wrote:
zen2010 wrote:I found this interesting link below...
https://www.mssociety.org.uk/ms-researc ... peline#PMS
This link is not available.
It works for me when I click on it.

User avatar
zen2010
Family Elder
Posts: 218
Joined: Mon Mar 15, 2010 3:00 pm
Location: Villeurbanne, France

Re: Progressive MS Pipeline

Post by zen2010 » Wed Aug 10, 2016 11:37 pm

NHE wrote:
UWE59 wrote:
zen2010 wrote:I found this interesting link below...
https://www.mssociety.org.uk/ms-researc ... peline#PMS
This link is not available.
It works for me when I click on it.
Hi,

Forget about the previous link and try the one below:
http://www.nationalmssociety.org/Resear ... #section-0

BR

User avatar
seeva
Family Elder
Posts: 505
Joined: Sun Jan 20, 2008 3:00 pm
Location: SYDNEY
Contact:

Re: LIPOIC ACID AN OVER THE COUNTER ANTIOXIDANT, SEEN TO SLO

Post by seeva » Wed Jul 12, 2017 1:00 am

HI Friends please read
https://multiplesclerosisnewstoday.com/ ... -patients/
regards
seeva

User avatar
zen2010
Family Elder
Posts: 218
Joined: Mon Mar 15, 2010 3:00 pm
Location: Villeurbanne, France

Re: Progressive MS Pipeline

Post by zen2010 » Mon Nov 05, 2018 7:28 am

Hi,

The next treatment for SPMS (and also PPMS I guess) will probably be this one:
https://multiplesclerosisnewstoday.com/ ... -for-spms/

Expected in US in March 2019
Later (so I guess end of the year) in Europe

User avatar
NHE
Volunteer Moderator
Posts: 5297
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: Progressive MS Pipeline

Post by NHE » Wed Nov 07, 2018 1:41 am

zen2010 wrote:The next treatment for SPMS (and also PPMS I guess) will probably be this one:
https://multiplesclerosisnewstoday.com/ ... -for-spms/

Expected in US in March 2019
Later (so I guess end of the year) in Europe
Regarding Siponimod, it sounds like PML could be a potential problem.

https://multiplesclerosisnewstoday.com/ ... 2-for-spms
Siponimod works by stopping the immune cells from entering the brain and spinal cord, preventing them from causing inflammation and damage to the myelin sheath.

Siponimod does this by binding to the sphingosine-1-phosphate (S1P) receptor found on the outside of immune cells, blocking its normal action. It interacts specifically with S1P receptor 1 and 5. The S1P receptor is important to trigger the release of immune cells from the lymph node and into the circulating blood. Siponimod keeps the immune cells trapped in the lymph node, slowing MS disease progression.
and...

https://mymsaa.org/publications/msresea ... siponimod/
Siponimod is a drug with a mechanism of action similar to Gilenya. Like Gilenya, it works at the S1P receptor family to block the movement of lymph cells from lymph nodes, however, siponimod appears to interact with less of the receptors than Gilenya does – with its primary actions at the S1P1 and the S1P5 receptors. Siponimod has a relatively short half-life compared to Gilenya, which means that the drug does not stay in the body as long. Researchers hope that these small differences will minimize cardiac issues.

User avatar
CureOrBust
Family Elder
Posts: 3367
Joined: Wed Jul 27, 2005 2:00 pm
Location: Sydney, Australia

Re: Progressive MS Pipeline

Post by CureOrBust » Fri Nov 23, 2018 2:07 am

zen2010 wrote:Hi,

The next treatment for SPMS (and also PPMS I guess) will probably be this one:
https://multiplesclerosisnewstoday.com/ ... -for-spms/

Expected in US in March 2019
Later (so I guess end of the year) in Europe
This trial http://www.thisisms.com/forum/drug-pipe ... 30179.html has already started. I am registered for the trial, but am on a wash out period of Gilenya (ie Siponimod's older brother); 9 months, so my first dosing is in feb Image. They have run a previous trial using autologous cells, and previous to that, a single original trial patient. From my understanding the original single guy improved, the second trial was supposedly successful based on a company bought up the rights, and is now running an allogeneic based trial. (see link, in the link) I reiterate, this trial has already started dosing patients. I tried to get onto the second trial, but although the dr was in Australia, he only included patients from his hospital Image

User avatar
CureOrBust
Family Elder
Posts: 3367
Joined: Wed Jul 27, 2005 2:00 pm
Location: Sydney, Australia

Re: Progressive MS Pipeline

Post by CureOrBust » Sun Sep 22, 2019 2:36 am

I finished my last dosing a number of months ago. However, I have notably progressed including a relapse. I am SPMS. I have received the second highest dosing.

I will be discussing with the trial Neuro about coming off the trial, and starting another DMD or restarting Gilenya.

Although the study is un-blinded, all the test/results are not seen until after the end of the trial. I think they want to test all the samples in one batch, so that there is no difference in the results induced by difference in testing over time. I am thinking of getting my GP to run an independent EBV test, to see if there is a change in that respect.

User avatar
NHE
Volunteer Moderator
Posts: 5297
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: Progressive MS Pipeline

Post by NHE » Sun Sep 22, 2019 3:52 pm

CureOrBust wrote:
Sun Sep 22, 2019 2:36 am
I finished my last dosing a number of months ago. However, I have notably progressed including a relapse. I am SPMS. I have received the second highest dosing.

I will be discussing with the trial Neuro about coming off the trial, and starting another DMD or restarting Gilenya.
Siponimod was recently approved as Mayzent.

viewforum.php?f=61

Its efficacy on slowing disability progression is not terribly impressive (this graph is from the prescribing information).


Image

ElliotB
Family Elder
Posts: 1934
Joined: Mon Feb 03, 2014 4:08 pm

Re: Progressive MS Pipeline

Post by ElliotB » Sun Sep 22, 2019 4:21 pm

That graph/chart looks surprising similar to one you posted recently in an Ocrevus thread (for Ocrevus, obviously):

viewtopic.php?f=58&t=30961

Interesting...

User avatar
CureOrBust
Family Elder
Posts: 3367
Joined: Wed Jul 27, 2005 2:00 pm
Location: Sydney, Australia

Re: Progressive MS Pipeline

Post by CureOrBust » Mon Sep 23, 2019 1:57 am

NHE wrote:
Sun Sep 22, 2019 3:52 pm
Siponimod was recently approved as Mayzent.
Its on my list of exit options for discussion. However, I do not think it has been approved in Australia. I think it is still under consideration of our equivalent of the FDA i.e. the TGA (Therapeutic Goods Administration) and for Govt funding under the PBA ( ie Pharmaceutical Benefits Scheme). Gilenya comes from >$2000 AUD a month down to $40 AUD a month.

PS: I am SPMS, no enhancing lesions, so Lemtrada is out.

User avatar
NHE
Volunteer Moderator
Posts: 5297
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: Progressive MS Pipeline

Post by NHE » Mon Sep 23, 2019 7:30 am

ElliotB wrote:
Sun Sep 22, 2019 4:21 pm
That graph/chart looks surprising similar to one you posted recently in an Ocrevus thread (for Ocrevus, obviously)
The Mayzent graph appears to be either distorted or the relative risk reduction calculation was done incorrectly. If one extends horizontal lines from the treatment plots over to the y axis, I get about 43% for the control treatment and about 36% for the Mayzent treatment.

Image

Relative risk reduction should be calculated as (controls-treated)/controls.
https://bestpractice.bmj.com/info/us/to ... late-risk/

This yields (43%-36%)/43% = 16.3% relative risk reduction.

Am I missing something? I just don't see how they got 21%.

User avatar
NHE
Volunteer Moderator
Posts: 5297
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: Progressive MS Pipeline

Post by NHE » Fri Sep 27, 2019 5:35 pm

NHE wrote:
Mon Sep 23, 2019 7:30 am
Relative risk reduction should be calculated as (controls-treated)/controls.
https://bestpractice.bmj.com/info/us/to ... late-risk/

This yields (43%-36%)/43% = 16.3% relative risk reduction.

Am I missing something? I just don't see how they got 21%.
A similar analysis of the Ocrevus data plot yields...

Relative risk: (46.71-38.86)/46.71 = 16.8%

I don't see how they get the claimed 24% ???

Post Reply
  • Similar Topics
    Replies
    Views
    Last post